![](/img/cover-not-exists.png)
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
Guy, Holly, Walder, Lydia, Fisher, MarkLanguage:
english
Journal:
PharmacoEconomics
DOI:
10.1007/s40273-018-0745-z
Date:
November, 2018
File:
PDF, 1.98 MB
english, 2018